The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...

Intellectual disabilities, food allergies, and asthma were all more common in children who took multiple courses of ...

For millions of people around the world, asthma is more than just a breathing problem—it is a chronic and often debilitating ...

Blue Cross Blue Shield mandates severe asthma patients self-administer drugs at home, unless their provider gets prior approval from the company.

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...